Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

SourceLilly Investors
Date Published09/17/2020
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Amgen
Reshoring category:Reshoring
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2020
Domestically, the work will be done:Both
City reshored to:Thousand Oaks
State(s) reshored to:CA
If relevant, work nearshored to:-
Industry(ies):Chemicals, biopharmaceutical
Product(s) reshoredneutralizing antibodies, LY-CoV-555
What domestic positive factors made reshoring more attractive?Eco-system synergies, Skilled workforce availability/training, Covid-19
Find Reshoring Articles